Following Procarta's success in raising fresh capital in a round led by Morningside Group Dr David Knowles has been invited to take the Chairmanship of the company. David is internationally renowned as a pioneer of antibacterial research and a successful developer of therapeutics.
David comes to Procarta with twenty years' experience in senior positions in major international pharmaceutical companies, including SmithKline Beecham, where he was Director of Molecular Biology. For the past ten years he has acted as CSO/R&D Director for several companies in the biotech sector in the UK (RiboTargets plc., British Biotech plc., Piramed Ltd, CellCentric) as well as advising other biotechs and Private Equity Funds in the UK, US, Europe and Asia.
"I am delighted that Procarta has secured this funding. The company's elegant therapeutic platform is potentially applicable to a wide range of bacterial diseases and Procarta can now advance its portfolio of much-needed anti-bacterials,"
- Dr Knowles